Following a postponement and an unusually contentious session, a national immunization advisory committee was scheduled to decide on Friday concerning altering the long-held guideline that all newborns be immunized against hepatitis B.
Fiery Exchange and a Postponed Decision
The first day of the meeting on Thursday was defined by heated debate over restricting access to the hepatitis B vaccine for infants and a choice to postpone the decision by a day to allow panelists additional time to scrutinize the phrasing. The panel, which advises the CDC on vaccine use, had previously delayed on two occasions.
“Is there any definitive data of harm of giving this vaccination before 30 days? Or is this conjecture?” asked one adviser.
In response, another attendee stated, “There is limited evidence about the enduring danger.”
Existing Recommendations and Likely Ramifications
The shot is presently advised for each baby within 24 hours of being born to halt contraction of hepatitis B, which can cause serious liver damage. It has been given to more than a billion persons for over thirty years.
The meeting in Atlanta presented no recent proof of injuries resulting from the vaccine. Specialists note any modification to the present hepatitis B vaccine regimen could have profound and widespread repercussions for infant and child health in the United States.
Committee Makeup and Recent Changes
The advisory panel can only make recommendations to the leader of the CDC. The committee's composition has undergone changes this week, with the declaration that the group's former head would depart for an formal position and be substituted with a cardiac doctor who has been questioning of other inoculations.
The panel includes several immunization doubters who are in agreement with a desire to overhaul – and possibly, in some cases, eliminate – traditional vaccine advisories.